Brief Communication Clinical Microbiology

Similar documents
Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification

Original Article Clinical Microbiology INTRODUCTION

MALDI-TOF mass spectrometry for direct bacterial identification

Int.J.Curr.Microbiol.App.Sci (2016) 5(9):

SUPPLEMENTARY MATERIAL

Abstract. Introduction

VITEK MS Implementation of Mass Spectrometry

Supplemental Digital Content

Tandem MS in Microbiology. Chris Doern, PhD D(ABMM) UT Southwestern Medical Center Dallas, TX

TITLE: MALDI-TOF Mass Spectrometry for Bacterial Species Identification: A Review of Diagnostic Accuracy and Clinical and Cost-Effectiveness

Received 1 March 2011/Returned for modification 19 April 2011/Accepted 20 May 2011

Direct Identification of Urinary Tract Pathogens from Urine Samples by Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Direct identification of bacteria from positive anaerobic BacT/Alert blood cultures by. Contents Category: Diagnostics, typing and identification

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the identification of beta-hemolytic streptococci

Consultation on the Revision of Carbapenem Breakpoints

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

RESEARCH ARTICLE Torres et al., Journal of Medical Microbiology 2017;66: DOI /jmm

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

National Surveillance of Nosocomial Septicemia (Hospital-wide)

Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry

Microorganisms direct identification from blood culture by matrixassisted laser desorption/ionization time-of-flight mass spectrometry

Infectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable

1430 West McCoy Lane Santa Maria, CA p:

Medical Microbiology, University Hospital of Liège, Liège, Belgium

HYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE

Optimizing MALDI-TOF Use. Clinical Impact Laboratory Impact

Outpatient treatment in women with acute pyelonephritis after visiting emergency department

The MALDI Biotyper An In Vitro Diagnostic System (IVD) for Identification of Bacteria and Yeasts with a Global Reach

Correlation between sputum and BAL cultures. 1. Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de

Supplementary Information. Ionization Mass Spectrometry

INFECTIOUS DISEASE. Page 2

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples

ESCMID Online Lecture Library. by author

Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory

Sep Oct Nov Dec Total

Matrix-assisted laser-desorption/ionization BIOTYPER: experience in the routine of a University hospital

MALDI-TOF mass spectrometry tools for microbial identification in archival document investigation

Received 22 December 2009/Returned for modification 26 January 2010/Accepted 4 March 2010

Int.J.Curr.Res.Aca.Rev.2017; 5(9): 10-14

Detection of microorganisms in blood specimens using matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a review

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 April - 30 June 2014

DIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05

Healthcare-associated infections acquired in intensive care units

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

Identification of bacteria directly from positive blood culture samples by DNA pyrosequencing of the 16S rrna gene

Molecular approaches in the diagnosis of sepsis in neutropenic patients with haematological malignances

Optimized Use of the MALDI BioTyper System and FilmArray BCID Panel for the Direct

Torres, Brian Carlmichael L., Ma. Luisa G. Daroy, Juan s. Lopez, Vanessa Oh, Marie Joan Loy, Prospero ma. Tuaño, and Ronald R. Matias Research and

Monitoring of Enhanced Surveillance for Severe and Fatal Pneumonia, 1 st January 31 st March 2015

Cell counting (EtBr) Before cell-lysis. Cell-lysis by 3% SDS beads beating. After cell-lysis

M O L E C U L A R G E N E T I C S

Aerobic bacteria isolated from diabetic septic wounds

Microsan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #

ZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg

La «Fast Microbiology» applicata alla sepsi: prospettive ed opportunità

Prospective Evaluation of a MALDI-TOF MS System in a Hospital Clinical Microbiology

General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since

Ramanath Karicheri 1, Beena Antony 2* Original Research Article. Abstract

Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Mongolia September 2012

OVERVIEW OF CURRENT IDENTIFICATION SYSTEMS AND DATABASES

MALDI-TOF Mass Spectrometry: A New Rapid ID Method in Clinical Microbiology

Laboratory Identification of Leptotrichia Species Isolated From Bacteremia Patients at a Single Institution

Correlation between the Treatment Result and Causative Bacteria in Amputation of Diabetic Foot

Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units

PATHOGEN DETECTION WITH THE FILMARRAY

DNA pyrosequencing of the 16S rrna

S. Q. van Veen,* E. C. J. Claas, and Ed J. Kuijper. Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

DISEASE OUTBREAKS SUMMARY

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

Abstract. Introduction. Material and Methods

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

Physical Properties Appearance: Clear Liquid Fragrance: Fragrance Free Form: Gel ph: INCI Name*

General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since

320 MBIO Microbial Diagnosis. Aljawharah F. Alabbad Noorah A. Alkubaisi 2017

Blue coloring. Enrichment medium for the simultaneous detection of total coliforms and Escherichia coli in water, foods and dairy products.

Evaluation of the feasibility of the VACUETTE Urine CCM tube for microbial testing of urine samples

KENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #

Discrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis

The characteristics of bacterial pathogens in cases of children with respiratory tract infection in Eastern area.

The 8 th International CASEE Conference Warsaw University of Life Sciences SGGW May 14-16, 2017

Comparison of the MALDI Biotyper system using Sepsityper specimen processing to

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel

Rapid identification of bacteria from positive blood culture bottles by MALDI-TOF MS following short-term incubation on solid media

Clinical experience with ceftazidime in urology in Japan

Rapid identification and resistance assessment: The future is mass spectrometry

Next Generation in Acne treatment. A new approach in Acne Treatment. GramaDerm. Advanced Acne Vulgaris Management with Microcyn Technology

PREVENTIVE MEDICINE - LABORATORY

M E D I C A L L A B O R A T O R Y

Syndromic Testing: The right test, the first time.

(multidrug-resistant Pseudomonas aeruginosa; MDRP)

Reducing Time to Result for Urinary Tract Pathogen Detection Utilizing Real-Time PCR Technology

Received 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005

Microbiology products. Liofilchem Chromatic

Streptococci facultative anaerobe

Transcription:

Brief Communication Clinical Microbiology Ann Lab Med 2017;37:531-535 https://doi.org/10.3343/alm.2017.37.6.531 ISSN 2234-3806 eissn 2234-3814 Comparison of a New Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Platform, ASTA MicroIDSys, With Bruker Biotyper for Identification Yangsoon Lee, M.D. 1, Ji Yeon Sung, M.D. 2, Hyunsoo Kim, M.D. 3, Dongeun Yong, M.D. 2, and Kyungwon Lee, M.D. 2 Department of Laboratory Medicine 1, Hanyang University College of Medicine, Seoul; Department of Laboratory Medicine 2, Severance Hospital, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine 3, National Police Hospital, Seoul, Korea Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, with its accuracy and speed, is widely used for bacterial identification. The ASTA MicroIDSys system (ASTA, Korea) was recently developed for species identification. We compared its performance with that of Bruker Biotyper (Bruker Daltonics, Germany). Microbes were recovered from sputum, urine, and pus samples from patients admitted to a tertiary care hospital in Korea from January to April 2016. Matrix solution (α-cyano-4-hydroxycinnamic acid) was used, and the peptide profiles acquired from the Microflex LT (Bruker Daltonics) and Tinkerbell LT (ASTA) were analyzed by using their respective software. From 5,322 isolates, Bruker Biotyper identified 163 species; fifty species from 4,919 isolates were identified more than 10 times, including Klebsiella pneumoniae (n = 571), Acinetobacter baumannii (n = 436), Pseudomonas aeruginosa (n = 358), Escherichia coli (n = 372), Staphylococcus aureus (n=511), S. epidermidis (n=444), Enterococcus faecium (n=262), E. faecalis (n=220), and Candida albicans (n=248). Identical, confidence scores ( 2.0 for Bruker Biotyper), and acceptable scores ( 140 for ASTA MicroIDSys) were obtained for 86.1% of isolates. Of 4,267 isolates, 99.2% showed acceptable scores in both systems. Results from the ASTA MicroIDSys showed good agreement with those from the Bruker Biotyper. The ASTA MicroIDSys could reliably identify clinically important microorganisms. Key Words: MicroIDSys, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Bruker Biotyper Received: January 16, 2017 Revision received: April 11, 2017 Accepted: July 19, 2017 Corresponding author: Dongeun Yong Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-2442 Fax: +82-2-364-1583 E-mail: deyong@yuhs.ac Korean Society for Laboratory Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Bacterial identification with automated instruments or conventional methods such as biochemical reactions takes a few hours to days in clinical microbiology laboratories. More rapid methods are necessary to diagnose and treat septic patients, and better accuracy is necessary for classifying complicated bacterial mixtures. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is widely used for bacterial identification in clinical microbiology laboratories because of its speed and accuracy [1-3]. Two in vitro diagnostic MALDI-TOF MS systems, the Bruker Biotyper MS (Bruker Daltonics, Bremen, Germany) and the Vitek MS (biomérieux, Marcy l Etoile, France), have been implemented in clinical microbiology laboratories worldwide and are routinely used for identifying bacterial and yeast isolates [4-6]. https://doi.org/10.3343/alm.2017.37.6.531 www.annlabmed.org 531

Recently, a new system, the ASTA MicroIDSys system (ASTA, Suwon, Korea), was developed for identification of clinically important pathogenic species. The ASTA MicroIDSys system consists of a linear-type MALDI-TOF MS, a database, and software for species identification by spectral pattern matching. The linear-type MALDI-TOF MS performs microbial MS analysis in the range of m/z = 2,000 20,000, with a mass accuracy and resolving power of 250 ppm and 1,000, respectively. The database contains reference MALDI spectra for 2,604 species. The MicroIDSys software employs an auto-selection algorithm for mass peaking of each species or strain of microorganism, in which the number of peaks that specifies each species is selected by the machine, based on pre-determined parameters, for better accuracy. The machine program itself selects parameters and masses as well as intensities of importance. In the present study, we compared the performance of the ASTA MicroIDSys system with that of the Bruker Biotyper MS system for identifying bacteria and yeast in routine clinical microbiology laboratory for the first time. A total of 5,322 isolates were recovered from clinical specimens of urine, sputum, tracheal aspirate, wounds, and pus from patients admitted to a tertiary care hospital in Korea in January-April 2016. The specimens were inoculated in appropriate media such as 5% sheep blood agar, MacConkey agar, or chocolate agar for bacteria and Sabouraud dextrose agar for yeast, and then incubated for 24 48 hr at 35 C. A single bacterial colony from the agar was smeared onto the target plate (Bruker Daltonics GmbH), the matrix solution (α-cyano-4-hydroxycinnamic acid) was overlaid on the spot, and the peptide profile was acquired from the Bruker Microflex LT system. For yeast analysis, suspicious colonies were smeared directly onto the target plate and overlaid with 1 µl 70% formic acid (Sigma-Aldrich, St. Louis, MO, USA) and matrix solution. The Microflex system had the Biotyper software 3.1 and the MALDI Biotyper reference library version 5.0.0.0. The mass spectra were analyzed according to the manufacturer s instructions. We used identification score values 2.0 for bacteria and yeast. After complete analysis using the Bruker Biotyper, the peptide profiles were obtained by using the ASTA MicroIDSys on the same target plates. All the mass profiles were then analyzed by using the MicroIDSys 1.0. The cut-off value was set at 140 for the ASTA MicroIDSys for all microorganisms. PCR and 16S rrna gene sequencing were performed for isolates that showed different from the Bruker Biotyper and ASTA MicroIDSys systems. Among the 5,322 isolates, 50 species (from 4,919 isolates) were isolated more than 10 times and analyzed for comparing the performances of the two MALDI-TOF MS systems. The were as follows: 2,222 gram-negative bacilli, 1,926 grampositive cocci, 413 Candida spp., and 385 other bacteria were detected. The most frequently isolated bacteria were Klebsiella pneumoniae (n=571), followed by Acinetobacter baumannii (n=436), Pseudomonas aeruginosa (n=358), Escherichia coli (n=372), Staphylococcus aureus (n=511), S. epidermidis (n= 444), Enterococcus faecium (n=262), E. faecalis (n=220), Corynebacterium striatum (n=201), and Candida albicans (n=248). From the 4,919 isolates studied, identical with confidence scores ( 2.0 for the Bruker Biotyper MS system) and acceptable scores ( 140 for the ASTA MicroIDSys system) were obtained for 4,234 (86.1%) isolates (Table 1). For the bacteria that are frequently isolated in clinical microbiology laboratories, the high agreement rates were as follows: K. pneumonia (100%), E. coli (98.9%), P. aeruginosa (100%), A. baumannii (99.8%), S. aureus (99.8%), S. epidermidis (99.8%), E. faecium (98.9%), and E. faecalis (99.1%). In addition, 4,841 (98.4%) isolates had a Bruker Biotyper score 1.7 and an ASTA MicroIDSys score 140. Only 78 (1.6%) isolates showed discrepant between the two systems. For these isolates, we performed 16S rrna gene sequencing. However, some species in the isolates were not accurately identified by either of the two methods; the 16S rrna gene sequence similarity was very high for Enterobacter and Streptococcus mitis groups [7]. From the observed discrepant between the two MALDI- TOF MS systems, we suspected that a known limitation of other MALDI-TOF MS systems might also be present in the ASTA MicroIDSys. Microorganisms are identified by MALDI-TOF MS systems using prerecorded protein spectra that are present in the system library, and these spectra are mostly based on ribosomal proteins. Therefore, MALDI-TOF MS systems are intrinsically limited to differentiate closely related species or strains of Salmonella spp., Raoutella, Klebsiella, Enterobacter, and Citrobacter [4, 8]. Identical, with scores between 1.7 and 2.0 for the Bruker Biotyper MS system and acceptable scores 140 for the ASTA MicroIDSys system, were obtained for 581 (11.8%) isolates; these included 242 (58.6%) Candida spp., 205 (10.6%) grampositive cocci, and 82 (3.7%) gram-negative bacilli. Only two isolates of C. albicans showed discrepant with an ASTA MicroIDSys score < 140. This result suggested that the threshold score for identification with the Bruker Biotyper should be 1.7, instead of the usual 2.0, in order to compensate for the spectrum quality of Candida spp. In contrast, the cutoff score used for identification by the ASTA MicroIDSys was the typical 532 www.annlabmed.org https://doi.org/10.3343/alm.2017.37.6.531

Table 1. Comparison of the for frequently isolated bacteria from the Bruker Biotyper and ASTA MicroIDSys systems N of isolates with identical/discrepant Score (Bruker): 2.0 Score (Bruker): 1.7, < 2.0 Total 140 < 140 140 < 140 Gram-negative bacilli Acinetobacter baumannii 420/1 3 12 435/1 Acinetobacter nosocomialis 18 18/0 Burkholderia cenocepacia 13 13/0 Citrobacter freundii 16 0/1 5 21/1 Elizabethkingia meningoseptica 11 2 13/0 Enterobacter aerogenes 75 0/1 1 76/1 Enterobacter asburiae 6/9 0/1 6/10 Enterobacter cloacae 42/3 1 3/1 46/4 Enterobacter kobei 13/4 0/1 13/5 Escherichia coli 360/1 0/2 8 0/1 368/4 Haemophilus influenzae 22 1 0/1 23/1 Klebsiella oxytoca 14 1 15/0 Klebsiella pneumoniae 539 1 31 571/0 Moraxella catarrhalis 19 1 20/0 Morganella morganii 25 25/0 Proteus mirabilis 26 26/0 Providencia rettgeri 14 1 15/0 Pseudomonas aeruginosa 349 1 8 358/0 Serratia marcescens 24 1 25/0 Stenotrophomonas maltophilia 96 1 11 108/0 N of subtotal (%) 2,102/18 11/4 82/3 0/2 2,195/27 (94.6/0.8) (0.5/0.2) (3.7/0.1) (0/0.1) (98.8/1.2) Gram-positive cocci Enterococcus avium 12 12/0 Enterococcus faecalis 204 1/1 10/1 1 218/2 Enterococcus faecium 250/2 0/1 6 259/3 Enterococcus raffinosus 7 5 12/0 Staphylococcus aureus 501/1 1 7 510/1 Staphylococcus capitis 16 8 24/0 Staphylococcus epidermidis 356 84/1 2 443/1 Staphylococcus haemolyticus 81 0/1 42/1 125/2 Staphylococcus hominis 14 7 21/0 Staphylococcus lugdunensis 8 1/1 10/1 Streptococcus agalactiae 41 3 44/0 Streptococcus anginosus 59 1 3 63/0 Streptococcus constellatus 14 1/1 16/1 (Continued to the next page) https://doi.org/10.3343/alm.2017.37.6.531 www.annlabmed.org 533

Table 1. Continued N of isolates with identical/discrepant Score (Bruker): 2.0 Score (Bruker): 1.7, < 2.0 140 < 140 140 < 140 Total Streptococcus mitis 20/1 0/1 3/1 0/1 27/4 Streptococcus oralis 30 1/2 4/3 2/4 46/9 Streptococcus parasanguinis 21 7 28/0 Streptococcus pneumoniae 14/10 2/2 4/3 35/15 Streptococcus salivarius 23 10 33/0 N of subtotal (%) 1,671/14 6/8 205/12 5/5 1,887/39 (86.8/0.7) (0.3/0.4) (10.6/0.6) (0.3/0.3) (98.0/2.0) Other bacteria Clostridium difficile 30 3 1 34 Clostridium hathewayi 13 1 14 Corynebacterium amycolatum 18 18 Corynebacterium striatum 190/1 0/4 6 196/5 Lactobacillus crispatus 8 1 13 22 Neisseria flavescens 11 2 13 Rothia mucilaginosa 28 27 1 56 N of subtotal (%) 298/1 1/4 52/0 2/0 353/5 (83.2/0.3) (0.3/1.1) (14.5/0) (0.6/0) (98.6/1.4) Candida spp. Candida albicans 93 0/1 149/3 0/2 242/6 Candida glabrata 27 21 48 Candida krusei 11 3 1 15 Candida parapsilosis 4 19 23 Candida tropicalis 28 50 0/1 79 N of subtotal (%) 163/0 0/1 242/3 1/3 406/7 (39.5/0) (0/0.2) (58.6/0.7) (0.2/0.7) (98.3/1.7) Total (%) 4,234/33 18/17 581/18 8/10 4,841/78 (86.1/0.7) (0.4/0.3) (11.8/0.4) (0.2/0.2) (98.4/1.6) 140 value itself, indicating that the power to discriminate between Candida species was higher in the ASTA MicroIDSys system than in the Bruker Biotyper system. The ASTA MicroIDSys MS system also showed high accuracy rates for overall identification of bacteria and Candida spp. from isolates. In this study, we identified clinically relevant bacteria and Candida species from clinical specimens using the ASTA MicroID- Sys system. Our findings on ASTA MicroIDSys system performance in the identification of bacteria and Candida species are in high agreement with findings from the Bruker Biotyper system. Especially for frequently isolated bacteria, such as K. pneumoniae, E. coli, P. aeruginosa, A. baumannii, S. aureus, S. epidermidis, E. faecium, and E. faecalis, high agreement rates (98.9 100%) were shown. In conclusion, the ASTA MicroIDSys has comparable identification capability to the Bruker Biotyper system. The ASTA MicroIDSys system can reliably identify microorganisms that are commonly isolated in clinical microbiological laboratories. Authors Disclosures of Potential Conflicts of Interest No potential conflicts of interest relevant to this article were reported. 534 www.annlabmed.org https://doi.org/10.3343/alm.2017.37.6.531

Acknowledgments This work was supported by the National Research Foundation of Korea (2014M3A9E5073818), the BioNano Health-Guard Research Center funded by the Ministry of Science, ICT & Future Planning (MSIP) of Korea as a Global Frontier Project (H- GUARD_2014M3A6B2060509), and the Ministry of Health & Welfare, Republic of Korea (HI14C1324). We are deeply grateful to Yong Ha In, Kyu Hwan Park, and Hyung Soon Park (ASTA Inc.), as well as to Hyungsun Kim and Sori Jong (The Research Institute of Antimicrobial Resistance, Yonsei University College of Medicine) for their help. REFERENCES 1. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009;49:543-51. 2. Claydon MA, Davey SN, Edwards-Jones V, Gordon DB. The rapid identification of intact microorganisms using mass spectrometry. Nat Biotechnol 1996;14:1584-6. 3. Martiny D, Busson L, Wybo I, El Haj RA, Dediste A, Vandenberg O. Comparison of the Microflex LT and Vitek MS systems for routine identification of bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2012;50:1313-25. 4. Bilecen K, Yaman G, Ciftci U, Laleli YR. Performances and reliability of Bruker Microflex LT and VITEK MS MALDI-TOF mass spectrometry systems for the identification of clinical microorganisms. Biomed Res Int 2015;2015:516410. 5. Richter SS, Sercia L, Branda JA, Burnham CA, Bythrow M, Ferraro MJ, et al. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system. Eur J Clin Microbiol Infect Dis 2013;32:1571-8. 6. Bessède E, Angla-Gre M, Delagarde Y, Sep Hieng S, Ménard A, Mégraud F. Matrix-assisted laser-desorption/ionization biotyper: experience in the routine of a university hospital. Clin Microbiol Infect 2011;17:533-8. 7. Janda JM and Abbott SL. 16S rrna gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol 2007;45:2761-4. 8. Wang H, Fan YY, Kudinha T, Xu ZP, Xiao M, Zhang L, et al. A comprehensive evaluation of the Bruker Biotyper MS and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of yeasts, part of the national china hospital invasive fungal surveillance net (CHIF-NET) study, 2012 to 2013. J Clin Microbiol 2016;54:1376-80. https://doi.org/10.3343/alm.2017.37.6.531 www.annlabmed.org 535

Supplemental Data Table S1. Comparison of the identified bacteria and yeast with score values 2.0 for the Bruker Biotyper system and 140 for the ASTA MicroIDSys system Gram-negative bacilli N of isolates with: Identical Discrepant Agreement rate (%) Acinetobacter baumannii 420 1 99.8 Acinetobacter nosocomialis 18 100.0 Burkholderia cenocepacia 13 100.0 Citrobacter freundii 16 100.0 Elizabethkingia meningoseptica 11 100.0 Enterobacter aerogenes 75 100.0 Enterobacter asburiae 6 9 40.0 Enterobacter cloacae 42 3 93.3 Enterobacter kobei 13 4 76.5 Escherichia coli 360 1 99.7 Haemophilus influenzae 22 100.0 Klebsiella oxytoca 14 100.0 Klebsiella pneumoniae 539 100.0 Moraxella catarrhalis 19 100.0 Morganella morganii 25 100.0 Proteus mirabilis 26 100.0 Providencia rettgeri 14 100.0 Pseudomonas aeruginosa 349 100.0 Serratia marcescens 24 100.0 Stenotrophomonas maltophilia 96 100.0 N of subtotal 2,102 18 99.2 Gram-positive cocci Enterococcus avium 12 100.0 Enterococcus faecalis 204 100.0 Enterococcus faecium 250 2 99.2 Enterococcus raffinosus 7 100.0 Staphylococcus aureus 501 1 99.8 Staphylococcus capitis 16 100.0 N of isolates with: Identical Discrepant Agreement rate (%) Staphylococcus epidermidis 356 100.0 Staphylococcus haemolyticus 81 100.0 Staphylococcus hominis 14 100.0 Staphylococcus lugdunensis 8 100.0 Streptococcus agalactiae 41 100.0 Streptococcus anginosus 59 100.0 Streptococcus constellatus 14 100.0 Streptococcus mitis 20 1 95.2 Streptococcus oralis 30 100.0 Streptococcus parasanguinis 21 100.0 Streptococcus pneumoniae 14 10 58.3 Streptococcus salivarius 23 100.0 N of subtotal 1,671 14 99.2 Other bacteria Clostridium difficile 30 100.0 Clostridium hathewayi 13 100.0 Corynebacterium amycolatum 18 100.0 Corynebacterium striatum 190 1 99.5 Lactobacillus crispatus 8 100.0 Neisseria flavescens 11 100.0 Rothia mucilaginosa 28 100.0 N of subtotal 298 1 99.7 Candida spp. Candida albicans 93 100 Candida glabrata 27 100 Candida krusei 11 100 Candida parapsilosis 4 100 Candida tropicalis 28 100 N of subtotal 163 100 Total 4,234 33 99.2 www.annlabmed.org https://doi.org/10.3343/alm.2017.37.6.531